4.5 Article

TAZ promotes PC2 degradation through a SCFβ-Trcp E3 ligase complex

Journal

MOLECULAR AND CELLULAR BIOLOGY
Volume 27, Issue 18, Pages 6383-6395

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/MCB.00254-07

Keywords

-

Funding

  1. National Research Foundation of Korea [과C6A2204] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
  2. NCI NIH HHS [CA 90992, R01 CA090992, R01 CA092520, R01 CA92520] Funding Source: Medline
  3. NIDDK NIH HHS [R01DK40703, R01 DK053357, R01DK53357, R01 DK040703, R01 DK051050, R01DK51050] Funding Source: Medline
  4. NIGMS NIH HHS [GM60594, R01 GM060594] Funding Source: Medline

Ask authors/readers for more resources

Studies of a TAZ knockout mouse reveal a novel function of the transcriptional regulator TAZ, that is, as a binding partner of the F-box protein beta-Trcp. TAZ(-/-) mice develop polycystic kidney disease (PKD) and emphysema. The calcium-permeable cation channel protein polycystin 2 (PC2) is overexpressed in kidneys of TAZ(-/-) mice as a result of decreased degradation via an SCF beta-Trcp E3 ubiquitin ligase pathway. Replacements of serines in a phosphodegron motif in TAZ prevent beta-Trcp binding and PC2 degradation. Coexpression of a cytoplasmic fragment of polycystin 1 blocks the PC2-TAZ interaction and prevents TAZ-mediated degradation of PC2. Depletion of TAZ in zebrafish also results in a cystic kidney accompanied by overexpression of PC2. These results establish a common role of TAZ across vertebrate species in a protein degradation pathway regulated by phosphorylation and implicate deficiencies in this pathway in the development of PKD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available